Well Referenced

Tag: Umbilical cord mesenchymal stem cells

Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial

This 2018 randomized controlled trial assessed the safety and efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in patients with moderate to severe Crohn’s disease (CD) unresponsive to long-term steroid therapy. Eighty-two patients were enrolled, with 41 receiving four weekly intravenous infusions of 1×10⁶ UC-MSCs/kg. After 12 months, the UC-MSC

Read More »
June 26, 2025 No Comments

Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

This 2014 multicenter clinical trial assessed the safety and efficacy of allogeneic umbilical cord mesenchymal stem cell transplantation (UC-MSCT) in 40 patients with active and refractory systemic lupus erythematosus (SLE). Patients received intravenous infusions of UC-MSCs on days 0 and 7. The treatment was well tolerated, with no transplantation-related adverse

Read More »
June 26, 2025 No Comments

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial)

This Phase 1/2 double-blind, placebo-controlled trial assessed the safety and efficacy of intravenous allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in 30 patients with chronic stable heart failure and reduced ejection fraction (HFrEF) under optimal medical therapy. Patients were randomized to receive a single infusion of UC-MSCs (1×10^6 cells/kg) or

Read More »
June 26, 2025 No Comments

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study

This prospective Phase I/II study evaluated the long-term safety and efficacy of intravenous umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy combined with disease-modifying anti-rheumatic drugs (DMARDs) in 64 patients with rheumatoid arthritis (RA). Patients received 2 × 10⁷ UC-MSCs via intravenous infusion and were followed for up to 3 years.

Read More »
June 26, 2025 No Comments